Solid Biosciences (SLDB) to PostQ3 Earnings: What's in Store?
Solid Biosciences (SLDB) will provide updates on its lead pipeline candidate,SGT-001, along with others when it releases third-quarter 2020 results.
Zacks · 3h ago
Tonix Provides Updates For Fibromyalgia, And Other News: The Good, Bad And Ugly Of Biopharma
Tonix Pharmaceuticals provides updates for fibromyalgia and COVID-19 studies.Innate Pharma proceeds with monalizumab trial, triggering milestone payment.Ultragenyx inks deal with Solid Biosciences for Duchenne Muscular Dystrophy program.
Seekingalpha · 19h ago
DDD, BCS, CVAC and MAT among premarket gainers
Socket Mobile (SCKT) +123% on Q3 results.Dogness (DOGZ) +60% after announcing partnership with Hangzhou Huayuan Pet Products and Shanghai Chongai Trading Co. Ltd.Zedge (ZDGE) +47% on Q4 results.Solid Biosciences (SLDB) +28% on announcing collaboration with Ultragenyx.Medigus (MDGS) +31% after its subsidiary
Seekingalpha · 5d ago
Ultragenyx, Solid Biosciences in pact for duchenne gene therapies
Ultragenyx Pharmaceutical and Solid Biosciences have entered a collaboration and license agreement to focus on the development and commercialization of new gene therapies for Duchenne muscular dystrophy.Solid has granted Ultragenyx
Seekingalpha · 5d ago
Ultragenyx And Solid Biosciences Announce Strategic Collaboration To Develop And Commercialize New Gene Therapies For Duchenne Muscular Dystrophy; Solid To Receive $40M Upfront Via Equity Investment And Up To $255M In Milestones Plus Royalty Payments
-Collaboration combines Solid’s differentiated microdystrophin construct and Ultragenyx’s HeLa PCL manufacturing platform for use with AAV8 and
Collaboration combines Solid’s differentiated microdystrophin construct and Ultragenyx’s HeLa PCL manufacturing platform for use with AAV8 and · 5d ago
Do Options Traders Know Something About Solid Biosciences (SLDB) Stock We Don't?
Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.
Zacks · 10/09 13:54
MYOK, TEF among premarket gainers
MyoKardia (MYOK) +59% as Bristol to acquire the company for $225/Share.Kosmos Energy (KOS) +50% as company closed a Gulf of Mexico facility with Beal Bank USA and Trafigura Trading LLC.Enlivex Therapeutics (ENLV) +49%.Corvus Pharmaceuticals
Seekingalpha · 10/05 12:28
FISV, JMIA, DRD and SLDB among after-hours movers
Gainers: [[SLDB]] +10.8%. [[GTHX]] +4%. [[LUB]] +3.7%. [[ATEN]] +3.5%.  [[DRD]] +3.4%.Losers: [[DPW]] -9%. [[CLB]] -6.5%. [[FISV]] -6.4%. [[BLDR]] -2.6%. [[JMIA]] -2.1%.
Seekingalpha · 10/02 21:47
Solid Biosciences (SLDB) Stock Will Surge Over 200% From Current Levels, Says Analyst
11 months ago, the U.S. Food and Drug Administration (FDA) shut down Solid Biosciences' (SLDB) "IGNITE DMD" Phase I/II clinical trial after one of the young patients involved in the trial suffered a "serious adverse event." Despite the patient in question recovering, no new patients
TipRanks · 10/02 19:56
Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 4th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Jennifer Ziolkowski, Chief Financial Officer, Joel Schneider, Chief Technology
GlobeNewswire · 10/02 11:30
Chardan raises Solid Biosciences price target 250%
Solid Biosciences ([[SLDB]] +81.0%) 'shines brightly' today after the FDA lifts hold on Duchenne study, evaluating its gene therapy candidate SGT-001. In November 2019, the study was put on clinical hold,
Seekingalpha · 10/01 19:53
Why Solid Biosciences Stock Has Doubled Today
The Food and Drug Administration allowed it to resume its Phase 1/2 trial of a drug to treat Duchenne muscular dystrophy. · 10/01 18:56
Mid-Afternoon Market Update: Nasdaq Jumps 150 Points; Selecta Biosciences Shares Plunge
Toward the end of trading Thursday, the Dow traded up 0.07% to 27801.83 while the NASDAQ rose 1.34% to 11,318. The S&P also rose, gaining 0.43% to 3,377.47.
Benzinga · 10/01 18:47
BBBY, AMAG, GNFT and ZSAN among midday movers
Gainers: Solid Biosciences (SLDB) +114%.Enlivex Therapeutics (ENLV) +45%.AMAG Pharmaceuticals (AMAG) +45%.American Equity Investment Life (AEL) +40%.Gridsum (GSUM) +36%.Bed Bath & Beyond (BBBY) +33%.Watford Holdings (WTRE) +26%.Advanced Emissions Solutions (ADES) +25%.Westwater Resources
Seekingalpha · 10/01 16:39
Mid-Day Market Update: Crude Oil Down 5.5%; Solid Biosciences Shares Jump
Midway through trading Thursday, the Dow traded up 0.39% to 27889.07 while the NASDAQ rose 0.95% to 11,273.94. The S&P also rose, gaining 0.51% to 3,380.26.
Benzinga · 10/01 16:39
Solid Biosciences, Enlivex Therapeutics leads healthcare gainers, Zosano Pharma, LogicBio Therapeutics among major losers
Gainers: Solid Biosciences (SLDB) +121%, Enlivex Therapeutics (ENLV) +49%, AMAG Pharmaceuticals (AMAG) +45%, ProPhase Labs (PRPH) +14%, Odonate Therapeutics (ODT) +14%.Losers: Zosano Pharma (ZSAN) -54%, LogicBio Therapeutics (LOGC) -31%, Selecta Biosciences (SELB) -31%, Genfit (GNFT) -15%, Soleno Therapeutics (SLNO) -13%.
Seekingalpha · 10/01 15:10
Why Solid Biosciences Stock Is Trading Higher Today
Solid Biosciences (NASDAQ: SLDB) shares are trading higher on Thursday after the company announced the FDA has lifted the clinical hold placed on the company's IGNITE DMD Phase 1/2 clinical trial.Solid Biosciences is a life science company. It is engaged in manufacturing of specialty and generic
Benzinga · 10/01 15:02
Mid-Morning Market Update: Markets Open Higher; PepsiCo Beats Q3 Views
Following the market opening Thursday, the Dow traded up 0.56% to 27936.69 while the NASDAQ rose 1.10% to 11,290.68. The S&P also rose, gaining 0.62% to 3,383.84.
Benzinga · 10/01 14:42
Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Company’s IGNITE DMD Phase I/II clinical trial
GlobeNewswire · 10/01 12:30
FDA lifts hold on Solid Bio's Duchenne study; shares rocket 61%
Thinly traded nano cap Solid Biosciences (SLDB) jumps 61% premarket on robust volume in reaction to the FDA's removal of the clinical hold placed on its Phase 1/2 clinical trial, IGNITE DMD,
Seekingalpha · 10/01 11:58
Webull provides a variety of real-time SLDB stock news. You can receive the latest news about SOLID BIOSCIENCE through multiple platforms. This information may help you make smarter investment decisions.
About SLDB
Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD. Its lead program, SGT-001, is an adeno-associated virus (AAV) microdystrophin gene therapy candidate, which focuses on enabling the systemic delivery of a shortened yet functional version of the dystrophin gene. The Company is examining small molecule and biologic candidates that may help manage the secondary disorders associated with DMD. It is developing Wearable support for patients with DMD. The hardware of its assistive devices is composed of three technologies: force generating actuators (or motors), electrically controlled clutches, and harness technology called Flex Grip.